New Delhi, June 24: Ranbaxy Laboratories has signed an exclusive licensing agreement with the US-based Atrix Laboratories Inc to develop and commercialise Eligard, a drug for prostate cancer, in India.

Ranbaxy officials were tight-lipped about the financial details of the deal and refused to even comment on the estimated size of the market for the drug.

The Indian pharma major has licensed the rights to register and market different formulations of the drug — Eligard 7.5 mg once-a-month, Eligard 22.5 mg three-month and Eligard 30 mg four-month — in the domestic market. Ranbaxy maintains the option to license the Eligard 45 mg six-month product.

Ranbaxy will be responsible for regulatory submissions and any studies that may be necessary to gain approval with Indian regulatory authorities.